The federal health committee is wrapping up its review of Bill-C64, An act respecting pharmacare. Want to know what happens next?
3Sixty’s new infographic explains the entire process including next steps after the bill passes.
@billdempster de 3Sixty partage ses réflexions sur ce qui promet d'être une année très chargée pour le secteur de la santé et des sciences de la vie à la Journée du Québec @CAHR_ACRSS
3Sixty is thrilled to announce two new additions to our growing team.
Please join us in welcoming Chris Gray and Doug Nanton to the 3Sixty family 👏👏
https://t.co/AEFlplXIqv
Your favourite duo is back for some more “eye spy with my little eye” on the way to next week’s IQVIA’s Industry Briefings in Toronto (Apr 16) and Montreal (Apr 17)! See you there!
Canadian Pathway to Rare Disease Drug Access: Sherry O’Quinn, @MorseConsult; Lindy Forte, @EVERSANAcompany ; Alexandra Chambers, @Bayer ; Joan Paulin, @PHACanad Bonnie Kam, @JanssenCanada, Rute Fernandes, @TakedaPharma moderated by Bill @3SixtyPA
Bill Dempster from @3sixtyPublicAffairs provides insights on the federal rare disease drug strategy & emerging provincial strategies: what they mean for pharmacies and how to shape implementation #NPSummit
The @pharmacy_CAN Specialty Pharmacy Summit is almost here! Day 2 Session Spotlights: Join Bill Dempster for "Implementing the Drugs for Rare Diseases Strategy" and Andrew Bakhit for "Technology Trends for Delivering Specialty Services" #NPSummit
Don’t miss this opportunity to be part of an informative dialogue where our speakers, and panelists will address the #evolving#pharmaceutical#policy and how the market adapts to a reset. The conference will be moderated by Bill Dempster, CEO, @3SixtyPA